Skip to content

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03640494
Enrollment
57
Registered
2018-08-21
Start date
2018-08-28
Completion date
2021-02-28
Last updated
2021-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic-Ischemic Encephalopathy

Keywords

Optical Coherence Tomography, Newborn, Infant

Brief summary

The purpose of this study is to develop a novel noninvasive bedside optical coherence tomography (OCT) imaging technique in newborn infants with HIE that improves our ability to assess the range of retinal effects from HIE and to diagnose and monitor treatments of HIE.

Interventions

DEVICEOptical Coherence Tomography

This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.

Sponsors

National Eye Institute (NEI)
CollaboratorNIH
Duke University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 20 Days
Healthy volunteers
No

Inclusion criteria

Infants are eligible if: * Admitted to the intensive care nursery, outborn or inborn, with a clinical diagnosis of HIE; and with the approval of the neonatologist * A parent or legal guardian provides written informed consent

Exclusion criteria

Potentially eligible infants will be excluded if: • Congenital or chromosomal anomaly that has a profound impact on brain or eye development (e.g. anencephaly, congenital cataract or Peter's anomaly) and infants for whom there has been a clinical decision to limit life support.

Design outcomes

Primary

MeasureTime frameDescription
Retinal injury morphologies on optical coherence tomographybirth to 10 daysComposite injury score from presence or absence of 5 morphologies on optical coherence tomography: 1) cystoid spaces,2) ganglion cell layer abnormality, 3) paracentral acute middle maculopathy, 4) hemorrhages, 5) photoreceptor ellipsoid zone at the fovea
Retinal nerve fiber layer thickness on optical coherence tomographybirth to 10 daysDeviation in the retinal nerve fiber layer thickness in the papillomacular bundle: 0 to 150 microns
Inner macular layer thickness on optical coherence tomographybirth to 10 daysDeviation in the thickness from internal limiting membrane to outer plexiform layer across the macula (500, 1000 and 2000μm from the fovea): 0 to 500 microns
Clinical hypoxic ischemic encephalopathy scorebirth to 6 hourshypoxic ischemic encephalopathy clinical score, within the first 6 hours of life, based on the modified Sarnat staging scale: mild, moderate or severe
MRI brain injury scorefrom 4 to 14 days after birthMRI scoring: global score of overall injury \[0-138\] characterized as mild \[0-11\], moderate \[12-32\], or severe \[\>32\].

Secondary

MeasureTime frameDescription
Choroidal thickness on optical coherence tomographybirth to 9 weeksDeviation in choroidal thickness across macula(500, 1000 and 2000μm from the fovea): 20 to 800 microns
Optic nerve head morphologybirth to 9 weeksoptic nerve head elevation and cup as a composite morphology: normal, excavated, elevated, bowing of retinal pigment epithelium
thickness of macular nerve fiber layerbirth to 9 weeksDeviation in nerve fiber layer thickness across macula(500, 1000 and 2000μm from the fovea): 0 to 100 microns
thickness of macular ganglion cell layerbirth to 9 weeksDeviation in ganglion cell layer thickness across macula(500, 1000 and 2000μm from the fovea): 0 to 200 microns
thickness of inner nuclear layerbirth to 9 weeksDeviation in total retinal thickness across macula (500, 1000 and 2000μm from the fovea): 0 to 400 microns
thickness of inner plexiform layerbirth to 9 weeksDeviation in inner plexiform layer thickness across macula (500, 1000 and 2000μm from the fovea): 0 to 100 microns
Longitudinal change in retinal injury morphologies on optical coherence tomographybirth to 9 weeksComposite injury score from presence or absence of 5 morphologies on optical coherence tomography: 1) cystoid spaces,2) ganglion cell layer abnormality, 3) paracentral acute middle maculopathy, 4) hemorrhages, 5) photoreceptor ellipsoid zone at the fovea
Longitudinal change in retinal nerve fiber layer thickness on optical coherence tomographybirth to 9 weeksDeviation in the retinal nerve fiber layer thickness in the papillomacular bundle: 0 to 150 microns
Longitudinal change in inner macular layer thickness on optical coherence tomographybirth to 9 weeksDeviation in the thickness from internal limiting membrane to outer plexiform layer across the macula (500, 1000 and 2000μm from the fovea): 0 to 500 microns
Late clinical hypoxic ischemic encephalopathy score1 to 8 daysComposite hypoxic ischemic encephalopathy severity score based on: examination after rewarming, early feeding behavior score, seizure score and electroencephalogram score
thickness of photoreceptor layerbirth to 9 weeksDeviation in total retinal thickness across macula(500, 1000 and 2000μm from the fovea): 0 to 200 microns
Total macular layer thickness on optical coherence tomographybirth to 9 weeksDeviation in total retinal thickness across macula (500, 1000 and 2000μm from the fovea): 0 to 500 microns
Center foveal thicknessbirth to 9 weeksDeviation in retinal thickness at the foveal center
Center ellipsoid zone thicknessbirth to 9 weeksDeviation in retinal thickness at the foveal center: 0 to 100 microns
pattern of MRI injuryfrom 4 to 14 days after birthPatterns of injury characterized descriptively as white matter, focal cortical, deep nuclear brain matter, or global based on the scoring methods of Bednadrek N et al.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026